GlassScriptPhysician profile
Lori M Williams
NPI 1801869672
$8,662.43
in general payments reported to CMS, 2019-2025
61 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,024 · 2022: $3,334 · 2023: $1,478 · 2024: $1,812 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,768 · Education: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,767.57 |
| Education | $536.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $631.71 | 2021-2025 | |
| Celgene Corporation | $522.37 | 2021-2024 | Pomalyst, Reblozyl, Opdualag |
| Seagen INC. | $435.24 | 2021-2023 | Tukysa, Padcev |
| E.R. Squibb & Sons, L.L.C. | $413.70 | 2021-2025 | Opdivo, Opdualag |
| Pfizer INC. | $402.16 | 2021-2025 | |
| Astellas Pharma US INC | $376.63 | 2021-2025 | Vyloy |
| Janssen Biotech, INC. | $372.21 | 2022-2025 | Darzalex, Erleada, Tecvayli |
| Genentech USA, INC. | $318.84 | 2021-2025 | Polivy, Tecentriq, Venclexta |
| Gilead Sciences, INC. | $300.77 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $299.73 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $283.60 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $241.86 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Genzyme Corporation | $225.71 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $219.51 | 2021-2025 | Enhertu, Lynparza |
| Array Biopharma INC | $218.41 | 2021-2024 | Mektovi, Braftovi, Lorbrena |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $211.55 | 2021-2025 | |
| Exelixis INC. | $193.28 | 2022-2025 | Cabometyx |
| Tersera Therapeutics LLC | $189.57 | 2022-2024 | Zoladex |
| Incyte Corporation | $179.94 | 2022-2025 | Jakafi, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $177.68 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $173.43 | 2022-2025 | Verzenio, Retevmo, Jaypirca |
| Emd Serono, INC. | $137.42 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.05 | 2022-2024 | Alunbrig, Fruzaqla |
| Sobi, INC | $107.92 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $104.51 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $94.62 | 2021-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $87.40 | 2022-2025 | |
| Daiichi Sankyo INC. | $84.11 | 2022-2025 | Enhertu |
| Rigel Pharmaceuticals, INC. | $83.29 | 2022-2025 | Gavreto, Rezlidhia, Tavalisse |
| Kite Pharma, INC. | $72.21 | 2021-2023 | |
| Karyopharm Therapeutics INC. | $71.50 | 2021-2022 | |
| Springworks Therapeutics, INC. | $70.22 | 2024-2025 | Ogsiveo |
| Genmab U.S., INC. | $67.03 | 2023-2025 | Tivdak |
| G1 Therapeutics, INC. | $66.78 | 2022-2023 | Cosela |
| Puma Biotechnology, INC. | $66.23 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $64.43 | 2022-2025 | Onivyde |
| Kyowa Kirin, INC. | $63.84 | 2021-2024 | Poteligeo |
| Bayer Healthcare Pharmaceuticals INC. | $60.92 | 2022 | |
| Novocure INC. | $60.21 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Apellis Pharmaceuticals, INC. | $58.03 | 2022-2025 | Empaveli |
| Eisai INC. | $56.57 | 2022 | |
| Taiho Oncology, INC. | $55.19 | 2021-2024 | |
| Stemline Therapeutics INC. | $51.69 | 2023-2025 | Orserdu |
| Emmaus Medical, INC. | $50.32 | 2022 | |
| Sumitomo Pharma America, INC. | $46.34 | 2024-2025 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $44.76 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $43.11 | 2022-2023 | Clonoseq |
| Mylan Institutional INC. | $42.49 | 2022 | |
| Acrotech Biopharma INC. | $40.17 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $37.67 | 2022-2023 | Pyrukynd |
| Beigene USA, INC. | $37.00 | 2021-2022 | |
| Mirati Therapeutics, INC. | $35.87 | 2024 | Krazati |
| Epizyme, INC. | $34.39 | 2021 | |
| Pharmaessentia USA Corporation | $31.99 | 2025 | Besremi |
| Geron Corporation | $21.23 | 2025 | Rytelo |
| Clovis Oncology, INC. | $20.91 | 2022 | |
| Genentech, INC. | $18.25 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.19 | 2024 | Cosela |
| Cti Biopharma Corp. | $15.44 | 2022 | |
| Syndax Pharmaceuticals, INC. | $15.10 | 2025 | |
| Blueprint Medicines Corporation | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.